Some authors have suggested that activation of cholinergic system through α7nAChR activation, using electrical vagus nerve stimulation or exogenous α7nAChR ligand exposure (such as nicotine or pharmacological compounds) could represent innovative therapeutic strategies to limit COVID-19-induced hypercytokinemia6,16–19. The gene discussed is CHRNA7; the disease is COVID-19.